HK1085396A1 - Use of 5-substituted nucleosides for reinforcing the apoptotic effect of cytostatic drugs - Google Patents
Use of 5-substituted nucleosides for reinforcing the apoptotic effect of cytostatic drugsInfo
- Publication number
- HK1085396A1 HK1085396A1 HK06105578A HK06105578A HK1085396A1 HK 1085396 A1 HK1085396 A1 HK 1085396A1 HK 06105578 A HK06105578 A HK 06105578A HK 06105578 A HK06105578 A HK 06105578A HK 1085396 A1 HK1085396 A1 HK 1085396A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- reinforcing
- apoptotic effect
- substituted nucleosides
- cytostatic drugs
- cytostatic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10313035A DE10313035A1 (de) | 2003-03-24 | 2003-03-24 | Methode zur Verstärkung der apoptotischen Wirkung von Zytostatika ohne Erhöhung toxischer Nebenwirkungen |
PCT/EP2003/013008 WO2004084917A1 (de) | 2003-03-24 | 2003-11-20 | Verwendung von 5-substituierten nukleosiden zur verstärkung der apoptotischen wirkung von zytostatika |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1085396A1 true HK1085396A1 (en) | 2006-08-25 |
Family
ID=32946099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06105578A HK1085396A1 (en) | 2003-03-24 | 2006-05-15 | Use of 5-substituted nucleosides for reinforcing the apoptotic effect of cytostatic drugs |
Country Status (14)
Country | Link |
---|---|
US (1) | US7713948B2 (es) |
EP (1) | EP1605952B1 (es) |
JP (1) | JP2006521283A (es) |
KR (1) | KR100854873B1 (es) |
CN (2) | CN100394920C (es) |
AT (1) | ATE361081T1 (es) |
AU (1) | AU2003296589B2 (es) |
BR (1) | BR0318204A (es) |
CA (1) | CA2519801C (es) |
DE (2) | DE10313035A1 (es) |
ES (1) | ES2285275T3 (es) |
HK (1) | HK1085396A1 (es) |
MX (1) | MXPA05010142A (es) |
WO (1) | WO2004084917A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006037786A1 (de) | 2006-08-11 | 2008-03-20 | Resprotect Gmbh | Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung |
US20090068286A1 (en) * | 2007-09-11 | 2009-03-12 | Resprotect, Gmbh | Method of treating cancer by administration of 5-substituted nucleosides |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU610344B2 (en) * | 1988-02-29 | 1991-05-16 | Taiho Pharmaceutical Co., Ltd. | 2'-deoxy-5-fluorouridine derivatives |
CN1051980A (zh) * | 1990-12-18 | 1991-06-05 | 四川大学 | 一种新的肿瘤标志物以及用该标志物检测肿瘤的方法 |
DE69407056T2 (de) * | 1993-09-14 | 1998-04-09 | Merrell Dow Pharma | 5-(1-fluorovinyl)-1h-pyrimidin-2,4-dion-derivate als antineoplastische mittel |
JPH11502515A (ja) * | 1995-02-01 | 1999-03-02 | フラウンホファー−ゲゼルシャフト・ツァ・フェルダリュング・デア・アンゲバンテン・フォルシュング・エー・ファウ | 細胞増殖抑制剤処理における耐性形成に対する5’置換ヌクレオシドの利用と、このヌクレオシドを含む医薬品 |
WO2001007088A2 (en) * | 1999-07-22 | 2001-02-01 | Newbiotics, Inc. | Methods for treating therapy-resistant tumors |
DE10108851A1 (de) * | 2001-02-23 | 2002-09-12 | Resprotect Gmbh | Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten |
-
2003
- 2003-03-24 DE DE10313035A patent/DE10313035A1/de not_active Withdrawn
- 2003-11-20 ES ES03816433T patent/ES2285275T3/es not_active Expired - Lifetime
- 2003-11-20 MX MXPA05010142A patent/MXPA05010142A/es active IP Right Grant
- 2003-11-20 AT AT03816433T patent/ATE361081T1/de active
- 2003-11-20 CN CNB2003801102017A patent/CN100394920C/zh not_active Expired - Fee Related
- 2003-11-20 US US10/550,013 patent/US7713948B2/en not_active Expired - Fee Related
- 2003-11-20 EP EP03816433A patent/EP1605952B1/de not_active Expired - Lifetime
- 2003-11-20 CA CA2519801A patent/CA2519801C/en not_active Expired - Fee Related
- 2003-11-20 BR BRPI0318204-5A patent/BR0318204A/pt not_active IP Right Cessation
- 2003-11-20 JP JP2004569859A patent/JP2006521283A/ja active Pending
- 2003-11-20 KR KR1020057017721A patent/KR100854873B1/ko active IP Right Grant
- 2003-11-20 DE DE50307207T patent/DE50307207D1/de not_active Expired - Lifetime
- 2003-11-20 CN CNA2008100969236A patent/CN101278941A/zh active Pending
- 2003-11-20 AU AU2003296589A patent/AU2003296589B2/en not_active Ceased
- 2003-11-20 WO PCT/EP2003/013008 patent/WO2004084917A1/de active IP Right Grant
-
2006
- 2006-05-15 HK HK06105578A patent/HK1085396A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US7713948B2 (en) | 2010-05-11 |
AU2003296589A1 (en) | 2004-10-18 |
US20060178338A1 (en) | 2006-08-10 |
WO2004084917A1 (de) | 2004-10-07 |
CN100394920C (zh) | 2008-06-18 |
ES2285275T3 (es) | 2007-11-16 |
AU2003296589B2 (en) | 2009-02-12 |
JP2006521283A (ja) | 2006-09-21 |
DE50307207D1 (de) | 2007-06-14 |
EP1605952B1 (de) | 2007-05-02 |
KR100854873B1 (ko) | 2008-08-28 |
CA2519801C (en) | 2010-03-23 |
CN1758918A (zh) | 2006-04-12 |
CN101278941A (zh) | 2008-10-08 |
MXPA05010142A (es) | 2005-11-17 |
CA2519801A1 (en) | 2004-10-07 |
KR20060002841A (ko) | 2006-01-09 |
DE10313035A1 (de) | 2004-10-07 |
EP1605952A1 (de) | 2005-12-21 |
BR0318204A (pt) | 2006-03-21 |
ATE361081T1 (de) | 2007-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1700032I1 (hu) | Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog | |
EP1646639B8 (en) | Nucleotide phosphoramidates as anticancer agents | |
EP1793865A4 (en) | GENETIC OR DRUG DELIVERY SYSTEM | |
GEP20115231B (en) | 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones | |
IL184872A0 (en) | Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers | |
IL185063A0 (en) | Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers | |
TW200800999A (en) | Novel compounds | |
WO2005123736A8 (de) | Neue 2-benzylaminodihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
EP2567964A3 (en) | Monomer Compositions for the Synthesis of RNA, Methods of Synthesis, and Methods of Deprotection | |
WO2007120333A3 (en) | Tetracyclic kinase inhibitors | |
MX2009014033A (es) | Producto de confiteria. | |
TNSN08191A1 (en) | Kinase inhibitors | |
LU92202I9 (es) | ||
IL178727A (en) | Tetrahydropyridothiophene derivatives and pharmaceutical compositions containing the same | |
WO2006097617A3 (fr) | Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux | |
ZA200801332B (en) | Pentacyclic kinase inhibitors | |
DK1526840T3 (da) | Nanopartikler til DNA administration til et målorgan | |
MX2009001433A (es) | Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica. | |
HK1085396A1 (en) | Use of 5-substituted nucleosides for reinforcing the apoptotic effect of cytostatic drugs | |
WO2008087329A3 (fr) | Nouveau médicament pour le traitement d'un cancer gastrique | |
BRPI0507985A (pt) | derivados de piperazina uréia para o tratamento de endometriose | |
TW200616642A (en) | CRP lowering agent | |
MX2007003463A (es) | Triciclos, su elaboracion y su uso como agentes farmaceuticos. | |
EP1667695A4 (en) | OLIGONUCLEOTIDES TARGETING PRION DISEASES | |
BRPI0410638A (pt) | derivados de azitromicina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20171120 |